{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:31:56Z","timestamp":1792783916377,"version":"4.5.0"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Philanthropia Fundation"},{"name":"Nuovo-Soldati"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.ejca.2018.03.006","type":"journal-article","created":{"date-parts":[[2018,4,23]],"date-time":"2018-04-23T06:32:39Z","timestamp":1524465159000},"page":"91-104","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":111,"special_numbering":"C","title":["Detection of immune-related adverse events by medical imaging in patients treated with anti-programmed cell death 1"],"prefix":"10.1016","volume":"96","author":[{"given":"Ahmed","family":"Mekki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1322-0710","authenticated-orcid":false,"given":"Laurent","family":"Dercle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Lichtenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lien","family":"Marabelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3482-3331","authenticated-orcid":false,"given":"Jean-Marie","family":"Michot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Lambotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Le Pavec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"De Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Balleyguier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Champiat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samy","family":"Ammari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.ejca.2018.03.006_bib1","doi-asserted-by":"crossref","first-page":"OF14","DOI":"10.1158\/2159-8290.CD-NB2013-074","article-title":"PD-1 inhibitor becomes \u201cbreakthrough therapy\u201d","volume":"3","year":"2013","journal-title":"Cancer Discov"},{"issue":"2","key":"10.1016\/j.ejca.2018.03.006_bib2","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ejca.2018.03.006_bib3","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2967\/jnumed.117.193011","article-title":"(18)F-FDG PET and CT scans detect new imaging patterns of response and progression in patients with Hodgkin lymphoma treated by anti-programmed death 1 immune checkpoint inhibitor","volume":"59","author":"Dercle","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ejca.2018.03.006_bib4","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ejca.2017.12.015","article-title":"Kinetics and nadir of responses to immune checkpoint blockade by anti-PD1 in patients with classical Hodgkin lymphoma","volume":"91","author":"Dercle","year":"2018","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2018.03.006_bib5","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.bulcan.2017.11.008","article-title":"Hodgkin lymphoma: current and future therapeutic strategies","volume":"105","author":"Turpin","year":"2018","journal-title":"Bull Cancer"},{"issue":"8","key":"10.1016\/j.ejca.2018.03.006_bib6","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1158\/1078-0432.CCR-16-1741","article-title":"Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-pd-1\/pd-L1","volume":"23","author":"Champiat","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2018.03.006_bib7","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ejca.2016.06.017","article-title":"Abscopal effect in a Hodgkin lymphoma patient treated by an anti-programmed death 1 antibody","volume":"66","author":"Michot","year":"2016","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.ejca.2018.03.006_bib8","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","article-title":"iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2018.03.006_bib9","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s00259-014-2938-9","article-title":"Nonsurgical giant cell tumour of the tendon sheath or of the diffuse type: are MRI or 18F-FDG PET\/CT able to provide an accurate prediction of long-term outcome?","volume":"42","author":"Dercle","year":"2015","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"1","key":"10.1016\/j.ejca.2018.03.006_bib10","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2967\/jnumed.117.193011","article-title":"18F-FDG PET and CT scans detect new imaging patterns of response and progression in patients with Hodgkin lymphoma treated by anti-programmed death 1 immune checkpoint inhibitor","volume":"59","author":"Dercle","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ejca.2018.03.006_bib11","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ejca.2016.05.031","article-title":"Rapid and objective CT scan prognostic scoring identifies metastatic patients with long-term clinical benefit on anti-PD-1\/-L1 therapy","volume":"65","author":"Dercle","year":"2016","journal-title":"Eur J Cancer"},{"issue":"7","key":"10.1016\/j.ejca.2018.03.006_bib12","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1200\/JCO.2015.66.1389","article-title":"Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma","volume":"35","author":"Weber","year":"2017","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2018.03.006_bib13","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1093\/annonc\/mdv623","article-title":"Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper","volume":"27","author":"Champiat","year":"2016","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2018.03.006_bib14","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1158\/2326-6066.CIR-15-0102","article-title":"Radiographic profiling of immune-related adverse events in advanced melanoma patients treated with ipilimumab","volume":"3","author":"Tirumani","year":"2015","journal-title":"Cancer Immunol Res"},{"issue":"4","key":"10.1016\/j.ejca.2018.03.006_bib15","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1093\/annonc\/mdw696","article-title":"Immune checkpoint inhibitors-related orchitis","volume":"28","author":"Brunet-Possenti","year":"2017","journal-title":"Ann Oncol"},{"issue":"24","key":"10.1016\/j.ejca.2018.03.006_bib16","doi-asserted-by":"crossref","first-page":"6051","DOI":"10.1158\/1078-0432.CCR-16-1320","article-title":"PD-1 inhibitor-related pneumonitis in advanced cancer patients: radiographic patterns and clinical course","volume":"22","author":"Nishino","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.ejca.2018.03.006_bib17","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1056\/NEJMc1505197","article-title":"Anti-PD-1-Related pneumonitis during cancer immunotherapy","volume":"373","author":"Nishino","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ejca.2018.03.006_bib18","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1158\/2326-6066.CIR-15-0267","article-title":"Anti-PD-1 inhibitor-related pneumonitis in non-small cell lung cancer","volume":"4","author":"Nishino","year":"2016","journal-title":"Cancer Immunol Res"},{"issue":"2","key":"10.1016\/j.ejca.2018.03.006_bib19","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00050-2017","article-title":"Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients","volume":"50","author":"Delaunay","year":"2017","journal-title":"Eur Respir J"},{"issue":"7","key":"10.1016\/j.ejca.2018.03.006_bib20","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1200\/JCO.2016.68.2005","article-title":"Pneumonitis in patients treated with anti\u2013programmed death-1\/programmed death ligand 1 therapy","volume":"35","author":"Naidoo","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2018.03.006_bib21","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.lungcan.2016.12.016","article-title":"Nivolumab-induced interstitial lung disease analysis of two phase II studies patients with recurrent or advanced non-small-cell lung cancer","volume":"104","author":"Kato","year":"2017","journal-title":"Lung Cancer"},{"issue":"3","key":"10.1016\/j.ejca.2018.03.006_bib22","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1378\/chest.12-1467","article-title":"Organizing pneumonia as a side effect of ipilimumab treatment of melanoma","volume":"143","author":"Barjaktarevic","year":"2013","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.ejca.2018.03.006_bib23","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1093\/jjco\/hyv199","article-title":"Nivolumab-induced organizing pneumonia in a melanoma patient","volume":"46","author":"Sano","year":"2016","journal-title":"Jpn J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2018.03.006_bib24","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.alit.2016.04.009","article-title":"Severe pneumonitis after nivolumab treatment in a patient with melanoma","volume":"65","author":"Watanabe","year":"2016","journal-title":"Allergol Int"},{"issue":"2","key":"10.1016\/j.ejca.2018.03.006_bib25","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1200\/JCO.2011.37.9693","article-title":"Ipilimumab-induced sarcoidosis in a patient with metastatic melanoma undergoing complete remission","volume":"30","author":"Vogel","year":"2012","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2018.03.006_bib26","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1177\/1078155216667635","article-title":"Sarcoidosis-like syndrome and lymphadenopathy due to checkpoint inhibitors","volume":"23","author":"Firwana","year":"2017","journal-title":"J Oncol Pharm Pract"},{"issue":"17","key":"10.1016\/j.ejca.2018.03.006_bib27","doi-asserted-by":"crossref","first-page":"e156","DOI":"10.1200\/JCO.2011.39.3298","article-title":"Pulmonary sarcoid-like granulomatosis induced by ipilimumab","volume":"30","author":"Berthod","year":"2012","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2018.03.006_bib28","doi-asserted-by":"crossref","first-page":"e272","DOI":"10.1016\/j.jaad.2013.07.028","article-title":"Cutaneous and pulmonary sarcoidosis-like reaction associated with ipilimumab","volume":"69","author":"Reule","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2018.03.006_bib29","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3389\/fphar.2017.00049","article-title":"Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy","volume":"8","author":"Kumar","year":"2017","journal-title":"Front Pharmacol"},{"issue":"11","key":"10.1016\/j.ejca.2018.03.006_bib30","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.2217\/imt.15.87","article-title":"Risk of gastrointestinal complications in cancer patients treated with immune checkpoint inhibitors: a meta-analysis","volume":"7","author":"Abdel-Rahman","year":"2015","journal-title":"Immunotherapy"},{"issue":"5","key":"10.1016\/j.ejca.2018.03.006_bib31","doi-asserted-by":"crossref","first-page":"W468","DOI":"10.2214\/AJR.12.9751","article-title":"Ipilimumab-associated colitis: CT findings","volume":"200","author":"Kim","year":"2013","journal-title":"AJR Am J Roentgenol"},{"issue":"14","key":"10.1016\/j.ejca.2018.03.006_bib32","doi-asserted-by":"crossref","first-page":"4373","DOI":"10.3748\/wjg.v21.i14.4373","article-title":"Ipilimumab associated colitis: an IpiColitis case series at MedStar georgetown university hospital","volume":"21","author":"Rastogi","year":"2015","journal-title":"World J Gastroenterol"},{"issue":"4","key":"10.1016\/j.ejca.2018.03.006_bib33","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/jgh.12888","article-title":"Ipilimumab-induced toxicities and the gastroenterologist","volume":"30","author":"Cheng","year":"2015","journal-title":"J Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.ejca.2018.03.006_bib34","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1093\/ecco-jcc\/jjv227","article-title":"Cancer immunotherapy with anti-CTLA-4 monoclonal antibodies induces an inflammatory bowel disease","volume":"10","author":"Marthey","year":"2016","journal-title":"J Crohns Colitis"},{"issue":"8","key":"10.1016\/j.ejca.2018.03.006_bib35","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ejca.2018.03.006_bib36","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1097\/RLU.0b013e318248549a","article-title":"Ipilimumab-induced colitis on FDG PET\/CT","volume":"37","author":"Lyall","year":"2012","journal-title":"Clin Nucl Med"},{"issue":"4","key":"10.1016\/j.ejca.2018.03.006_bib37","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1158\/2326-6066.CIR-16-0302","article-title":"Diagnostic comparison of CT scans and colonoscopy for immune-related colitis in ipilimumab-treated advanced melanoma patients","volume":"5","author":"Garcia-Neuer","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.ejca.2018.03.006_bib38","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.lungcan.2016.07.001","article-title":"Immune-related pancreatitis secondary to nivolumab in a patient with recurrent lung adenocarcinoma: a case report","volume":"99","author":"Ikeuchi","year":"2016","journal-title":"Lung Cancer"},{"issue":"11","key":"10.1016\/j.ejca.2018.03.006_bib39","doi-asserted-by":"crossref","first-page":"e528","DOI":"10.1097\/RLU.0000000000000940","article-title":"Pancreatitis secondary to anti-programmed death receptor 1 immunotherapy diagnosed by FDG PET\/CT","volume":"40","author":"Alabed","year":"2015","journal-title":"Clin Nucl Med"},{"issue":"5","key":"10.1016\/j.ejca.2018.03.006_bib40","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.pan.2013.08.001","article-title":"Acute pancreatitis associated with molecular targeted therapies: a retrospective review of the clinico-radiological features, management and outcome","volume":"13","author":"Tirumani","year":"2013","journal-title":"Pancreatology"},{"issue":"4","key":"10.1016\/j.ejca.2018.03.006_bib41","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1007\/s10637-013-9939-6","article-title":"Ipilimumab associated hepatitis: imaging and clinicopathologic findings","volume":"31","author":"Kim","year":"2013","journal-title":"Invest N Drugs"},{"issue":"3","key":"10.1016\/j.ejca.2018.03.006_bib42","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1097\/RLU.0000000000000606","article-title":"Ipilimumab-induced hepatitis on 18F-FDG PET\/CT in a patient with malignant melanoma","volume":"40","author":"Raad","year":"2015","journal-title":"Clin Nucl Med"},{"issue":"2","key":"10.1016\/j.ejca.2018.03.006_bib43","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1530\/EJE-10-0833","article-title":"Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy","volume":"164","author":"Min","year":"2011","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"10.1016\/j.ejca.2018.03.006_bib44","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1093\/jjco\/hyw036","article-title":"Nivolumab-induced thyroid dysfunction","volume":"46","author":"Tanaka","year":"2016","journal-title":"Jpn J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2018.03.006_bib45","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s11102-015-0671-4","article-title":"Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights","volume":"19","author":"Faje","year":"2016","journal-title":"Pituitary"},{"issue":"9","key":"10.1016\/j.ejca.2018.03.006_bib46","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.3174\/ajnr.A1623","article-title":"Ipilimumab-induced hypophysitis: MR imaging findings","volume":"30","author":"Carpenter","year":"2009","journal-title":"AJNR Am J Neuroradiol"},{"issue":"10","key":"10.1016\/j.ejca.2018.03.006_bib47","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1507\/endocrj.EJ16-0161","article-title":"Nivolumab-induced hypophysitis in a patient with advanced malignant melanoma","volume":"63","author":"Okano","year":"2016","journal-title":"Endocr J"},{"issue":"2","key":"10.1016\/j.ejca.2018.03.006_bib48","doi-asserted-by":"crossref","first-page":"94","DOI":"10.3340\/jkns.2012.51.2.94","article-title":"A case of pituitary metastasis from breast cancer that presented as left visual disturbance","volume":"51","author":"Kim","year":"2012","journal-title":"J Korean Neurosurg Soc"},{"issue":"1","key":"10.1016\/j.ejca.2018.03.006_bib49","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/CJI.0000000000000060","article-title":"Arthritis and tenosynovitis associated with the anti-PD1 antibody pembrolizumab in metastatic melanoma","volume":"38","author":"Chan","year":"2015","journal-title":"J Immunother"},{"issue":"4","key":"10.1016\/j.ejca.2018.03.006_bib50","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/CJI.0000000000000163","article-title":"Nivolumab causing a polymyalgia rheumatica in a patient with a squamous non\u2013small cell lung cancer","volume":"40","author":"Bernier","year":"2017","journal-title":"J Immunother"},{"issue":"19","key":"10.1016\/j.ejca.2018.03.006_bib51","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1001\/jama.1985.03360190069027","article-title":"Remitting seronegative symmetrical synovitis with pitting edema: RS3PE syndrome","volume":"254","author":"Mccarty","year":"1985","journal-title":"Jama"},{"key":"10.1016\/j.ejca.2018.03.006_bib52","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2017-211216","article-title":"Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment","author":"Belkhir","year":"2017","journal-title":"Annals Rheum Dis"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804918307135?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804918307135?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,20]],"date-time":"2022-08-20T14:10:19Z","timestamp":1661004619000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804918307135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":52,"alternative-id":["S0959804918307135"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2018.03.006","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Detection of immune-related adverse events by medical imaging in patients treated with anti-programmed cell death 1","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2018.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}